Skip to main content
SpringerLink
Log in

Lansoprazole Oro-Dispersible Tablet

Pharmacokinetics and Therapeutic Use in Acid-Related Disorders

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Lansoprazole is an H+, K+-adenosine triphosphatase proton pump inhibitor (PPI) used for management of acid-related disorders. Lansoprazole has been reformulated as an oro-dispersible tablet (LODT) that quickly dissolves in the mouth without water. In healthy adults the safety and bioavailability of LODT 15–30mg, taken without water or dispersed in water, were found to be comparable with those of lansoprazole 15–30mg capsules. Moreover, the bioavailability of LODT administered without water has been found to be similar to that of water-dispersed LODT given via a nasogastric tube. In a clinical study, the vast majority of patients found the mouth feel of LODT acceptable and almost all found it easy to take. A comparison of LODT with esomeprazole in a small group of patients with non-erosive reflux disease showed similar decreases in symptoms from baseline and no significant difference between groups.

In conclusion, LODT is effective, bioequivalent to the capsule formulation and acceptable to patients. LODT offers an alternative dose administration method to all patients requiring a PPI, especially those who have difficulty swallowing, and may increase patient convenience and compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Levin TR, Schmittdiel JA, Kunz K, et al. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997; 103: 520–8

    Article  PubMed  CAS  Google Scholar 

  2. Scott M, Gelhot AR. Gastroesophageal reflux disease: diagnosis and management. Am Fam Physician 1999; 59: 1161–9, 1199

    PubMed  CAS  Google Scholar 

  3. Locke III GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448–56

    Article  PubMed  Google Scholar 

  4. Tolman KG, Sanders SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65–70

    Article  PubMed  CAS  Google Scholar 

  5. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51(3): 460–82

    Article  PubMed  CAS  Google Scholar 

  6. Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665–70

    Article  PubMed  CAS  Google Scholar 

  7. Swan SK, Hoyumpa AM, Merritt GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999; 13 Suppl. 3: 11–7

    Article  PubMed  CAS  Google Scholar 

  8. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20(1): 38–49

    Article  PubMed  CAS  Google Scholar 

  9. Stedman CAM, Barclay ML. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963–78

    Article  PubMed  CAS  Google Scholar 

  10. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001; 61(12): 1801–33

    Article  PubMed  CAS  Google Scholar 

  11. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. NSAID-Associated Gastric Ulcer Prevention Study Group. Arch Intern Med 2002; 162(2): 169–75

    CAS  Google Scholar 

  12. Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997; 41(6): 735–9

    CAS  Google Scholar 

  13. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician 2002; 66(2): 273–80

    PubMed  Google Scholar 

  14. Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related disorders in the US [published erratum appears in Drugs 2002; 62 (15): 2183]. Drugs 2002; 62(7): 1091–118

    Article  PubMed  CAS  Google Scholar 

  15. Tateno M, Nakamura N. Phase I study of lansoprazole antiulcer agent: capsule form. J Clin Ther Med 1991; 7: 51–62

    Google Scholar 

  16. Tabata T, Kashihara T, Hirai S, et al. Effect of gastric pH on the absorption of a new antiulcer drug (lansoprazole) in the beagle dog. J Biopharm Sci 1991; 2: 319–28

    CAS  Google Scholar 

  17. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67: 1–5

    Article  PubMed  CAS  Google Scholar 

  18. Freston JW, Chiu YL, Mulford DJ, et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 361–7

    Article  PubMed  CAS  Google Scholar 

  19. Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004; 19: 1211–5

    Article  PubMed  CAS  Google Scholar 

  20. Taubel J, Lorch U, Baxter G. A comparison of the bioavailability of 15mg lansoprazole oro-dispersible tablet dispersed in the mouth with prior dispersal in water [abstract]. Gut 2003; 52 Suppl. 6: A61

    Google Scholar 

  21. Freston JW, Kukulka MJ, Lloyd E, et al. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. Aliment Pharmacol Ther 2004; 20: 407–11

    Article  PubMed  CAS  Google Scholar 

  22. Gerloff J, Mignot A, Barth H, et al. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 1996; 50: 293–7

    Article  PubMed  CAS  Google Scholar 

  23. Iwasaki K, Yoshikawa Y, Shibata N, et al. Evaluation of fast disintegrating lansoprazole tablet in human subjects. Drug Metab Pharmacokinet 2004; 19: 227–35

    Article  PubMed  CAS  Google Scholar 

  24. Pumfrey B, Baxter G. Patient administration and acceptability of the lansoprazole oro-dispersible tablet [abstract]. Gut 2004; 53 Suppl. 6: A289

    Google Scholar 

  25. Morelli P, Gambardella F, Tuccillo M, et al. Lansoprazole orally disintegrating tablets (LODT): an Italian study of awareness, use and satisfaction of this new formulation among physicians [abstract]. Digest Liver Dis 2005; 37 Suppl. 1: S81

    Google Scholar 

  26. Baldi F, Cavoli C, Ghersi S, et al. A comparison of the new lansoprazole orally disintegrating tablets (LODT) with esomeprazole in patients with non erosive reflux disease [abstract]. Digestive Disease Week; 2005 May 14–19; Chicago

  27. Sanders SW, Tolman KG, Greski PA, et al. The effects of lansoprazole, a new H+,K(+)-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992; 6: 359–72

    Article  PubMed  CAS  Google Scholar 

  28. Hongo M, Ohara S, Hirasawa Y, et al. Effect of lansoprazole on intragastric pH: comparison between morning and evening dosing. Dig Dis Sci 1992; 37: 882–90

    Article  PubMed  CAS  Google Scholar 

  29. Fraser AG, Sawyerr AM, Smith MS, et al. Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects. Aliment Pharmacol Ther 1996 Aug; 10(4): 523–7

    Article  PubMed  CAS  Google Scholar 

  30. Fraser AG, Sawyerr AM, Hudson M, et al. Morning versus evening dosing of lansoprazole 30mg daily on twenty-four-hour intragastric acidity in healthy subjects. Aliment Pharmacol Ther 1996; 10: 523–7

    Article  PubMed  CAS  Google Scholar 

  31. Baldi F, Morselli-Labate AM, Cappiello R, et al. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol 2002; 97: 1357–64

    Article  PubMed  CAS  Google Scholar 

  32. Shanley C, O’Loughlin G. Dysphagia among nursing home residents: an assessment and management protocol. J Gerontol Nurs 2000; 26: 35–48

    PubMed  CAS  Google Scholar 

  33. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 2000; 154: 150–4

    CAS  Google Scholar 

Download references

Acknowledgements

The author thanks Takeda Chemical Industries for supporting the publication of this manuscript and for supporting the clinical study on LODT (recently presented at the Digestive Disease Week).

Author information

Authors and Affiliations

  1. Department of Gastroenterology, S. Orsola Malpighi Hospital, Via Massarenti 9, Bologna, 40138, Italy

    Fabio Baldi

Authors
  1. Fabio Baldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabio Baldi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baldi, F. Lansoprazole Oro-Dispersible Tablet. Drugs 65, 1419–1426 (2005). https://doi.org/10.2165/00003495-200565100-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565100-00007

Keywords

Search

Navigation